Tag: genomics
-
Harnessing Big Data for Precision Medicine
13 February 2016. Precision medicine aims to match individualized genomic data with therapies to provide personalized treatments for people with disease. A panel today (13 February) at the American Association for Advancement of Science or AAAS 2016 annual meeting, described how big data — finding insights in large data sets — help make precision medicine…
-
Gene Editing Enlisted to Fight Citrus Greening
11 February 2016. Plant scientists at University of California in Riverside plan to use genome editing to develop varieties of citrus fruit resistant to a bacterial disease devastating crops in the U.S. and other parts of the world. The five-year research project led by UC-Riverside plant pathologist Wenbo Ma is funded by a $4 million…
-
$45M Raised by Protein Folding Drug Discovery Company
10 February 2016. A company discovering new treatments that address errant folding of proteins causing neurological disorders raised $45 million in its first venture funding round. Yumanity Therapeutics, a spin-off enterprise from the Whitehead Institute affiliated with MIT, started in December 2014 and aims to discover therapies for neurodegenerative diseases caused by misfolded proteins. Yumanity…
-
Tick Genome Sequenced, Control Strategies ID’ed
10 February 2016. A research consortium on three continents sequenced the genome of the black-legged tick, the insect responsible for Lyme disease and other conditions. The team of 93 authors from 46 institutions, led by entomologist Catherine Hill at Purdue University, published its findings in yesterday’s (9 February) issue of the journal Nature Communications, with…
-
Ebola Monitoring System Devised with Genome Sequencing
3 February 2016. An international team of scientists and engineers designed a mobile system using a hand-held genome sequencing device that provided real-time monitoring of the Ebola outbreak in West Africa in 2015. Researchers led by microbiologists Nicholas Loman and Joshua Quick at University of Birmingham in the U.K. published their findings in today’s (3…
-
Genome-Editing Company Raises $94 Million in IPO
3 February 2016. Editas Medicine, developer of treatments for disease that harness editing of the human genome, is raising $94.4 million in its initial public stock offering. The company, trading on the Nasdaq exchange under the symbol EDIT, issued 5.9 million shares priced at $16.00. As of 12 noon on 3 February, the stock is…
-
Illumina Providing Genomic Analysis for Precision Medicine
1 February 2016. Illumina Inc., a developer of genetic systems, is analyzing genomic data at four medical centers to integrate with patients’ electric health records for precision medicine. The San Diego company’s analytical services are expected to sequence and characterize the genomes of more than 200,000 individuals in the U.S. and Canada. Medical centers taking…
-
$100K Challenge Seeks Reinvented Clinical Trials
28 January 2016. A challenge at Harvard Business School seeks proposals for better ways of conducting clinical trials that bring to market faster new precision diagnostics and therapies. The competition has a total prize purse of $100,000 and an initial deadline of 13 March 2016. Precision medicine is the term given to emerging practices bringing…
-
Eye Disease Gene Defect Repaired with CRISPR
27 January 2016. Gene editing techniques repaired a defective gene in stem cells from an individual with retinitis pigmentosa, an inherited eye disease. The team from Columbia University and University of Iowa reported its findings in today’s (27 January) issue of Scientific Reports. Retinitis pigmentosa is a family of genetic eye disorders that result in damage…
-
Safety, Activity Assessed in New Duchenne Drug
25 January 2016. An early-stage clinical shows an experimental drug for Duchenne muscular dystrophy is safe for patients and produces the desired chemical activity in the body. Results of the trial, conducted by Catabasis Pharmaceuticals were released today. The Cambridge, Massachusetts company says it is now extending the study to test the drug against a…